Free tool
FAERS Monitor: Cotellic
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 206192 or its brand name (Cotellic, Cobimetinib Fumarate). Reports on generic versions are filed under their own applications.
Reports
4,436
Serious
3,673
83% of reports
Hospitalization
2,006
Death reported
588
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use482
- diarrhoea446
- rash402
- pyrexia368
- death253
- nausea235
- fatigue221
- vomiting185
- no adverse event183
- acute kidney injury139
- asthenia134
- photosensitivity reaction133
- rash maculo-papular125
- anaemia122
- drug reaction with eosinophilia and systemic symptoms120
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 16 |
| 2014 | 26 |
| 2015 | 86 |
| 2016 | 455 |
| 2017 | 583 |
| 2018 | 706 |
| 2019 | 556 |
| 2020 | 370 |
| 2021 | 362 |
| 2022 | 342 |
| 2023 | 239 |
| 2024 | 368 |
| 2025 | 194 |
| 2026 | 131 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,723 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| photosensitivity reactionSignal | 133 | 38.5 | 32.5 | 4,785 |
| rash maculo-papularSignal | 125 | 26.8 | 22.5 | 3,063 |
| drug reaction with eosinophilia and systemic symptomsSignal | 120 | 22.2 | 18.6 | 2,401 |
| pyrexiaSignal | 368 | 5.0 | 4.6 | 1,209 |
| no adverse eventSignal | 183 | 4.8 | 4.2 | 550 |
| rashSignal | 402 | 4.4 | 4.0 | 1,065 |
| acute kidney injurySignal | 139 | 4.3 | 3.7 | 352 |
| diarrhoeaSignal | 446 | 3.3 | 3.0 | 725 |
| anaemiaSignal | 122 | 3.0 | 2.5 | 166 |
| off label useSignal | 482 | 2.6 | 2.4 | 498 |
| vomiting | 185 | 1.9 | 1.6 | 75 |
| asthenia | 134 | 1.7 | 1.4 | 38 |
| nausea | 235 | 1.4 | 1.2 | 28 |
| death | 253 | 1.4 | 1.2 | 29 |
| fatigue | 221 | 1.3 | 1.2 | 20 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.